TargetMol

Tacedinaline

Product Code:
 
TAR-T1888
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1888-10mg10mg£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1888-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1888-50mg50mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1888-100mg100mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1888-200mg200mg£208.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1888-500mg500mg£367.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Tacedinaline (CI994) is a selective class I HDAC inhibitor with potential antineoplastic activity.
CAS:
112522-64-2
Formula:
C15H15N3O2
Molecular Weight:
269.304
Pathway:
DNA Damage/DNA Repair; Apoptosis; Chromatin/Epigenetic
Purity:
0.9912
SMILES:
CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N
Target:
Apoptosis; HDAC

References

1. Moradei OM, et al. J Med Chem. 2007, 50(23), 5543-5546. 2. Loprevite M, et al. A Oncol Res, 2005, 15(1), 39-48. 3. Gediya LK, et al. Bioorg Med Chem, 2008, 16(6), 3352-3360. 4. LoRusso PM, et al. Invest New Drugs, 1996, 14(4), 349-356. 5. Hubeek I, et al. Oncol Rep, 2008, 19(6), 1517-1523.